Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B: Symptoms and treatment
Hepatitis B (Hep B, HBV) What is Hepatitis? Hepatitis is inflammation of the liver. One of the primary causes of hepatitis is a viral infection. There are several viruses that may cause acute hepatitis (temporary liver inflammation), or chronic hepatitis

The cost-effectiveness of using hepatitis A/B combined vaccine versus hepatitis B vaccine alone for high-risk heterosexuals
Rein DB et al. - According to estimates, vaccinating with combination vaccine resulted in a cost of $120,000 per quality adjusted life year gained (2.79 times the 2005 United States Gross Domestic Product per capita), a ratio that is less favorable than

Hepatitis
What do drugs, alcohol, premarital and unprotected sex, tattoos and body piercings have in common? ?The In Thing? WRONG They're all things your parents probably lecture you about avoiding, but there's another connection as well - they can all lead to

UPDATES AND COMMENTARY RSS Feed

The Hepatitis Vaccine That Does Double Duty
People who have Hepatitis C and have not been vaccinated against Hepatitis A or Hepatitis B could benefit from the combined hepatitis vaccine....

Medical Spas May Pose Hepatitis Risk
Since medical spas are offering more treatments involving the use of needles, the potential for Hepatitis C transmission is rising. Learn about some of the spa treatment techniques that pose hepatitis transmission dangers, as well as five ways to increase...

Hepatitis B Treatment May Reduce Pancreatic Cancer Risk
While several theories are attempting to explain the connection, scientists are unsure why those with Hepatitis B appear to have a 2 1/2 fold increase in risk for developing pancreatic cancer. Once the link is understood, Hepatitis B treatment may...

Hepatology 1998 Aug;28(2):341-346

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic Hepatitis C not responding to interferon alone: results of a randomized, controlled trial.

Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E, Rizzetto M, Saracco G

Dipartimento di Gastroenterologia, Ospedale Molinette, Universita di Torino, Italy.


We conducted a three-arm, randomized trial in 96 patients with chronic Hepatitis C who did not respond to interferon alfa to compare treatments. Group 1 (33 patients) received ribavirin alone (1,000 mg/daily for 6 months) followed by interferon alfa n-3 alone (3 MU thrice weekly for 6 months); group 2 (33 patients) received ribavirin plus interferon alfa n-3 for 6 months at the above doses; and group 3 (30 patients) received interferon alfa n-3 alone (3 MU thrice weekly for 6 months). At the end of treatment, 3 patients (10%) in group 1, 13 (41%) in group 2, and 5 (17%) in group 3 had normal alanine transaminase (ALT) levels (group 2 vs. groups 1 and 3, P = .008). After 6 months of follow-up, only 4 patients (12.5%) in group 2 still had normal ALT values (P = .03). At the end of therapy, Hepatitis C virus (HCV) RNA was no longer detectable by polymerase chain reaction in 4 (13%), 9 (27%), and 2 (7%) patients, respectively, in groups 1, 2, and 3 (P = NS). Six months posttherapy, only 5 (15%) patients in group 2 were still HCV RNA negative (P = .02). At the time of follow-up liver biopsy, performed 6 months after the end of treatment, a significant improvement of the necroinflammatory scores was observed among group 2 patients (P = .01) but not in the other two groups. Side effects reflected the profile of each drug as monotherapy; mild hemolytic anemia was the most frequent side effect caused by ribavirin. In conclusion, concomitant administration of ribavirin and interferon alfa n-3 was significantly superior to the sequential schedule or interferon alfa n-3 monotherapy in inducing a sustained response in patients with chronic Hepatitis C who had not responded to interferon alone. However, combination therapy at the dose and duration adopted in this study is capable of modifying the natural course of the disease in only a minority of these patients.

PMID: 9695995, UI: 98359166

Vikki Shaw

Hepatitis Central

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 13 Oct 2008